[THE INVESTOR] Celltrion’s order amount in the second quarter was its highest ever, said eBEST Investment and Securities on June 25, maintaining a “buy” recommendation and 450,000 won (US$403.70) target price. 

It has signed a 144.6 billion won sales contract with Celltrion Healthcare to supply Remsima and Truxima. This is addition to a 71.1 billion won contract to supply Truxima to the subsidiary on June 11. This pushed the total amount in the second quarter to 215.7 billion won, up 7.9 percent on-year, said analyst Shin Jae-hun.

The deals are based on steady exports of Remsima to Europe and a hike in demand for Truxmia as well as solid revenue from Inflectra in the US, said the analyst. 

By Hwang You-mee (glamazon@heraldcorp.com)